Maintaining product quality of a monoclonal antibody through all phases of clinical development creates many challenges. Changes in cell line, cell line host, media and process conditions can all affect product quality attributes as a product moves from early to late development. All of these factors must be balanced with the desire to maintain protein production levels. Product quality attributes can be impacted by a number of these factors. A case study will be presented on the efforts to maintain product quality when switching cell lines from early to late stage. The effects of media composition and process conditions on product quality attributes will be examined
The integrated continuous bioprocess provides an innovative way to produce protein drugs with flexib...
The integrated continuous bioprocess provides an innovative way to produce protein drugs with flexib...
The development of a biosimilar introduces many unique challenges compared to that of a novel drug. ...
Product quality control without compromising productivity has been a major goal in biotherapeutics p...
Biopharmaceutical therapeutic development timelines can be reduced by quickly generating material to...
Product quality is a result of the entire production pro-cess including protein sequence, cell subst...
An overview of the production of antibodies by CHO cells and its requirements in terms of process de...
Speed to clinic often does not allow for in-depth manufacturing process development and understandin...
One of the key goals in process development for monoclonal antibodies is to improve productivity and...
In this talk we will present an overview of our findings on influencing and controlling product qual...
Recent improvements in volumetric antibody productivity (often in excess of 5 g/L) have been achieve...
International audienceAdverse immune responses severely hamper the success of biopharmaceutical ther...
From pre-clinical to Phase III, Biogen’s upstream process for a recombinant protein underwent a numb...
International audienceAdverse immune responses severely hamper the success of biopharmaceutical ther...
International audienceAdverse immune responses severely hamper the success of biopharmaceutical ther...
The integrated continuous bioprocess provides an innovative way to produce protein drugs with flexib...
The integrated continuous bioprocess provides an innovative way to produce protein drugs with flexib...
The development of a biosimilar introduces many unique challenges compared to that of a novel drug. ...
Product quality control without compromising productivity has been a major goal in biotherapeutics p...
Biopharmaceutical therapeutic development timelines can be reduced by quickly generating material to...
Product quality is a result of the entire production pro-cess including protein sequence, cell subst...
An overview of the production of antibodies by CHO cells and its requirements in terms of process de...
Speed to clinic often does not allow for in-depth manufacturing process development and understandin...
One of the key goals in process development for monoclonal antibodies is to improve productivity and...
In this talk we will present an overview of our findings on influencing and controlling product qual...
Recent improvements in volumetric antibody productivity (often in excess of 5 g/L) have been achieve...
International audienceAdverse immune responses severely hamper the success of biopharmaceutical ther...
From pre-clinical to Phase III, Biogen’s upstream process for a recombinant protein underwent a numb...
International audienceAdverse immune responses severely hamper the success of biopharmaceutical ther...
International audienceAdverse immune responses severely hamper the success of biopharmaceutical ther...
The integrated continuous bioprocess provides an innovative way to produce protein drugs with flexib...
The integrated continuous bioprocess provides an innovative way to produce protein drugs with flexib...
The development of a biosimilar introduces many unique challenges compared to that of a novel drug. ...